The primary purpose of this study is to demonstrate the long-term (3 years) favorable visual acuity and adverse event outcomes for the Clareon® Intraocular Lens (IOL) compared to historical safety and performance endpoint (SPE) rates as reported in EN ISO 11979-7:2014. The secondary purpose of this study is to evaluate the refractive outcomes obtained with up to 3 years follow-up in eyes implanted with the Clareon® IOL.